Studies showed remission
from Crohn’s disease and
ulcerative colitis symptoms
at 1 year.
Individual results may vary.
PRESCRIBING INFO
MEDICATION GUIDE
IMPORTANT SAFETY INFORMATION
Serious Infections
- Your doctor should check you for TB before starting
STELARA® and watch you closely for signs and symptoms of TB during treatment withSTELARA® . - If your doctor feels that you are at risk for TB, you may be treated for TB before and during treatment with
STELARA® .
You should not start taking
Before starting
- think you have an infection or have symptoms of an infection such as:
- fever, sweats, or chills
- muscle aches
- cough
- shortness of breath
- blood in phlegm
- weight loss
- warm, red, or painful skin or sores on your body
- diarrhea or stomach pain
- burning when you urinate or urinate more often than normal
- feel very tired
- are being treated for an infection or have any open cuts.
- get a lot of infections or have infections that keep coming back.
- have TB, or have been in close contact with someone with TB.
After starting
Cancers
Posterior Reversible Encephalopathy Syndrome (PRES)
PRES is a rare condition that affects the brain and can cause death. The cause of PRES is not known. If PRES is found early and treated, most people recover. Tell your doctor right away if you have any new or worsening medical problems including: headache, seizures, confusion, and vision problems.
Serious Allergic Reactions
Serious allergic reactions can occur. Stop using
Lung Inflammation
Cases of lung inflammation have happened in some people who receive
Before receiving
- have any of the conditions or symptoms listed above for serious infections, cancers, or PRES.
- ever had an allergic reaction to
STELARA® or any of its ingredients. Ask your doctor if you are not sure. - are allergic to latex. The needle cover on the prefilled syringe contains latex.
- have recently received or are scheduled to receive an immunization (vaccine). People who take
STELARA® should not receive live vaccines. Tell your doctor if anyone in your house needs a live vaccine. The viruses used in some types of live vaccines can spread to people with a weakened immune system, and can cause serious problems. You should not receive the BCG vaccine during the one year before receivingSTELARA® or one year after you stop receivingSTELARA® . - have any new or changing lesions within psoriasis areas or on normal skin.
- are receiving or have received allergy shots, especially for serious allergic reactions.
- receive or have received phototherapy for your psoriasis.
- are pregnant or plan to become pregnant. It is not known if
STELARA® can harm your unborn baby. You and your doctor should decide if you will receiveSTELARA® . - are breastfeeding or plan to breastfeed. It is thought that
STELARA® passes into your breast milk. - talk to your doctor about the best way to feed your baby if you receive
STELARA® .
Tell your doctor about all the medicines you take, including prescription and over‐the‐counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.
When prescribed
- Use
STELARA® exactly as your doctor tells you to. -
STELARA® is intended for use under the guidance and supervision of your doctor. In children 6 years and older, it is recommended thatSTELARA® be administered by a healthcare provider. If your doctor decides that you or a caregiver may give your injections ofSTELARA® at home, you should receive training on the right way to prepare and injectSTELARA® . Your doctor will determine the right dose ofSTELARA® for you, the amount for each injection, and how often you should receive it. Do not try to injectSTELARA® yourself until you or your caregiver have been shown how to injectSTELARA® by your doctor or nurse.
Common side effects of
Please click to read the full Prescribing Information and Medication Guide for
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‐800‐FDA‐1088.
cp-124932v3
© Janssen Biotech, Inc. 2021 02/21 cp-140704v3